Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.45 |
| ▸ | PDE2A | O00408 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9096936 | 0.90 | PDE5A (0.47) | PDE5A | |
| Hydrochloric Acid SCHEMBL4219637 | 0.82 | PDE5A (0.58) | PDE5APDE2A | |
| SCHEMBL7787705 | 0.81 | CTSL (0.41) | PDE5APDE2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6722823 | 0.76 | PDE5A (0.57) | PDE5APDE2A | |
| SCHEMBL7796197 | 0.74 | PDE4A (0.44) | PDE5APDE2AKDM4E | |
| Hydrochloric Acid SCHEMBL7914734 | 0.73 | PDE5A (0.60) | PDE5APDE2A | |
| SCHEMBL7503452 | 0.72 | PDE5A (0.71) | PDE5APDE2A | |
| SCHEMBL27376213 | 0.71 | ALDH1A1 (0.42) | PDE5APDE2AKDM4EMEN1USP2 | |
| SCHEMBL8863081 | 0.69 | PDE4A (0.51) | PDE5APDE2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL7794732 | 0.66 | PDE4A (0.49) | PDE5APDE2AKDM4EMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | PDE5A 2260/4885PDE2A 1782/4885KDM4E 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.